All articles tagged with #meningioma
Pfizer is sued in the US by women claiming its contraceptive Depo-Provera caused brain tumors, with allegations that the company failed to warn about the risks, leading to a growing number of lawsuits and a court hearing to address the issue of liability and regulatory warnings.
A study suggests that long-term use of the contraceptive pill desogestrel may slightly increase the risk of developing non-cancerous brain tumors called meningiomas, especially after more than five years of continuous use. The risk is small, and the tumors often regress after stopping the medication. No increased risk was found with levonorgestrel, another progestogen. Women should discuss contraceptive options with their healthcare providers, considering these findings.
Claire Love was diagnosed with a meningioma, a common brain tumour, at age 35, which she suspects was linked to her long-term use of the contraceptive jab Depo-Provera. Recent studies suggest a higher risk of meningioma associated with the contraceptive, raising concerns about informed consent and potential legal actions. Her case highlights the possible health risks of hormonal contraceptives and the importance of awareness and monitoring.
New research suggests that women taking the mini-pill containing desogestrel for more than five years may have a slightly increased risk of developing benign brain tumours called meningiomas, though the overall risk remains very low. Experts advise women not to be alarmed and to consult their doctors if concerned, as the increased risk disappears within a year of stopping the medication.
A large French study suggests that using the progestogen-only contraceptive pill desogestrel for more than five years may slightly increase the risk of developing benign brain tumors called meningiomas, but the risk diminishes after stopping the medication. Short-term use does not appear to increase risk, and the findings highlight the importance of healthcare provider consultation for women on long-term contraceptives.
A Merseyside woman, Hayley Burrows, was diagnosed with a large brain tumour just hours before giving birth to her son via emergency C-section, after suffering seizures. She underwent surgery nine weeks postpartum, facing significant physical and emotional challenges, highlighting the importance of awareness about brain tumours which can develop silently for years.
Prolonged use of certain progestogen hormone drugs, such as medrogestone and medroxyprogesterone acetate, is associated with an increased risk of developing intracranial meningioma, a type of brain tumor. This study is the first to assess the risk associated with progestogens used by millions of women worldwide, and further research is needed to better understand this risk. The study found no excess risk of meningioma for progesterone, dydrogesterone, or hormonal intrauterine systems, but further studies are urgently needed to gain a better understanding of this risk.